NuGen Medical Devices Inc.
NGMD.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -75.03% | -25.07% | 205.89% | 197.06% | 199.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -75.03% | -25.07% | 205.89% | 197.06% | 199.06% |
| Cost of Revenue | -74.85% | -36.31% | 190.01% | 181.61% | 188.28% |
| Gross Profit | -75.22% | -12.39% | 222.50% | 213.50% | 210.07% |
| SG&A Expenses | -25.39% | -41.27% | -21.96% | -41.07% | -33.93% |
| Depreciation & Amortization | -21.18% | -27.53% | -7.08% | -10.37% | -7.91% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.83% | -39.79% | -15.03% | -33.65% | -27.38% |
| Operating Income | 19.86% | 41.51% | 26.91% | 44.04% | 36.69% |
| Income Before Tax | -46.46% | 73.99% | 57.59% | 79.11% | 44.31% |
| Income Tax Expenses | 629.41% | -101.50% | -43.75% | -68.67% | -79.52% |
| Earnings from Continuing Operations | -47.24% | 74.11% | 57.54% | 79.07% | 44.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.24% | 74.11% | 57.54% | 79.07% | 44.44% |
| EBIT | 19.86% | 41.51% | 26.91% | 44.04% | 36.69% |
| EBITDA | 23.41% | 47.12% | 30.67% | 47.99% | 40.02% |
| EPS Basic | -38.12% | 76.45% | 61.75% | 81.49% | 57.31% |
| Normalized Basic EPS | 2.72% | 58.47% | 44.20% | 66.52% | 44.74% |
| EPS Diluted | -38.12% | 76.45% | 61.75% | 81.49% | 57.31% |
| Normalized Diluted EPS | 2.72% | 58.47% | 44.20% | 66.52% | 44.74% |
| Average Basic Shares Outstanding | 5.82% | 7.49% | 10.65% | 16.77% | 28.01% |
| Average Diluted Shares Outstanding | 5.82% | 7.49% | 10.65% | 16.77% | 28.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |